Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.44M | 3.35M | 2.22M | 1.83M | 1.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 187.20K | 800.00 | 800.00 | 800.00 | -186.40K |
| Total Operating Expenses | 28.06M | 22.21M | 13.49M | 9.78M | 6.14M |
| Operating Income | -28.06M | -22.21M | -13.49M | -9.78M | -6.14M |
| Income Before Tax | -17.60M | -19.70M | -14.24M | -8.78M | -6.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.60 | -19.70 | -14.24 | -8.78 | -6.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.60M | -19.70M | -14.24M | -8.78M | -6.38M |
| EBIT | -28.06M | -22.21M | -13.49M | -9.78M | -6.14M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.07 | -2.43 | -1.94 | -1.23 | -0.95 |
| Normalized Basic EPS | -1.29 | -1.52 | -1.21 | -0.77 | -0.59 |
| EPS Diluted | -2.07 | -2.43 | -1.94 | -1.24 | -0.95 |
| Normalized Diluted EPS | -1.29 | -1.52 | -1.21 | -0.77 | -0.59 |
| Average Basic Shares Outstanding | 34.42M | 31.67M | 29.12M | 27.52M | 24.76M |
| Average Diluted Shares Outstanding | 34.42M | 31.67M | 29.12M | 28.00M | 25.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |